PT2061561E - Composições para tratar o cancro - Google Patents

Composições para tratar o cancro

Info

Publication number: PT2061561E
Authority: PT; Portugal
Prior art keywords: compositions; treating cancer; cancer; hydroxylase; steroid
Prior art date: 2006-08-25

Application number

PT78373263T

Other languages

English (en)

Inventor

Alan H Auerbach

Arie S Belldegrun

Original Assignee

Janssen Oncology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-25

Filing date

2007-08-23

Publication date

2013-10-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2061561(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-08-23 Application filed by Janssen Oncology Inc filed Critical Janssen Oncology Inc

2013-10-09 Publication of PT2061561E publication Critical patent/PT2061561E/pt

Links

206010028980 Neoplasm Diseases 0.000 title abstract 3
201000011510 cancer Diseases 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
229940122124 17,20 lyase inhibitor Drugs 0.000 abstract 2
239000002246 antineoplastic agent Substances 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
150000003431 steroids Chemical class 0.000 abstract 2
229940124597 therapeutic agent Drugs 0.000 abstract 2
MDHIWBNJNHUBJL-VMXHOPILSA-N (8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC=C21 MDHIWBNJNHUBJL-VMXHOPILSA-N 0.000 abstract 1
229960004103 abiraterone acetate Drugs 0.000 abstract 1
UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PT78373263T 2006-08-25 2007-08-23 Composições para tratar o cancro PT2061561E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US92150606P	2006-08-25	2006-08-25

Publications (1)

Publication Number	Publication Date
PT2061561E true PT2061561E (pt)	2013-10-09

Family

ID=38916904

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT78373263T PT2061561E (pt)	2006-08-25	2007-08-23	Composições para tratar o cancro
PT121605869T PT2478907T (pt)	2006-08-25	2007-08-23	Composições para tratar o cancro

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT121605869T PT2478907T (pt)	2006-08-25	2007-08-23	Composições para tratar o cancro

Country Status (20)

Country	Link
EP (3)	EP3804730A1 (pt)
JP (10)	JP2010501575A (pt)
KR (4)	KR20090059126A (pt)
CN (2)	CN104306977A (pt)
AU (6)	AU2007287098C1 (pt)
CA (1)	CA2661422C (pt)
CY (2)	CY1115477T1 (pt)
DK (2)	DK2061561T3 (pt)
ES (2)	ES2869343T3 (pt)
HR (2)	HRP20130961T1 (pt)
HU (1)	HUE054495T2 (pt)
IL (3)	IL197211A0 (pt)
LT (1)	LT2478907T (pt)
NO (2)	NO20091190L (pt)
NZ (1)	NZ597830A (pt)
PL (2)	PL2478907T3 (pt)
PT (2)	PT2061561E (pt)
RS (2)	RS52956B (pt)
SI (2)	SI2061561T1 (pt)
WO (1)	WO2008024484A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2478907T3 (pl)	2006-08-25	2021-10-25	Janssen Oncology, Inc.	Kompozycje do leczenia nowotworu
US20080051380A1 (en)	2006-08-25	2008-02-28	Auerbach Alan H	Methods and compositions for treating cancer
US20090124587A1 (en) *	2007-07-12	2009-05-14	Auerbach Alan H	METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
PE20090931A1 (es) *	2007-10-29	2009-08-03	Takeda Pharmaceutical	Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa
CN102558274B (zh) *	2010-12-08	2014-10-15	深圳万乐药业有限公司	一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) *	2010-12-20	2012-07-11	天津药物研究院	α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
SG10201600077RA (en)	2011-01-11	2016-02-26	Glaxosmithkline Llc	Combination
WO2012135781A1 (en) *	2011-04-01	2012-10-04	Genentech, Inc.	Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
US20120295932A1 (en) *	2011-05-17	2012-11-22	Western Connecticut Health Network, Inc.	Method for the treatment of cancer
CN103070828B (zh) *	2011-10-26	2016-01-27	山东新时代药业有限公司	一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) *	2011-10-31	2013-05-15	南京卡文迪许生物工程技术有限公司	醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) *	2012-05-04	2012-06-20	Jagotec Ag	Improvements in or relating to organic compounds
RU2014154009A (ru) *	2012-06-06	2016-08-10	Новартис Аг	Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
NZ744456A (en)	2012-09-26	2019-09-27	Aragon Pharmaceuticals Inc	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
CN103800296A (zh) *	2012-11-13	2014-05-21	重庆医药工业研究院有限责任公司	一种稳定的阿比特龙口服固体药物组合物及其制备方法
PL2945628T3 (pl) *	2013-01-15	2020-09-21	Aragon Pharmaceuticals, Inc.	Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
US20150246060A1 (en)	2013-03-15	2015-09-03	Iceutica Inc.	Abiraterone Acetate Formulation and Methods of Use
US20140287039A1 (en) *	2013-03-15	2014-09-25	Iceutica Inc.	Abiraterone Acetate Formulation
WO2014165779A1 (en) *	2013-04-04	2014-10-09	Exelixis, Inc.	Drug combinations to treat cancer
US20150157646A1 (en)	2013-09-27	2015-06-11	Iceutica Inc.	Abiraterone Steroid Formulation
MX2016004265A (es) *	2013-10-01	2016-07-08	Novartis Ag	Combinacion.
CN109806266A (zh) *	2013-10-01	2019-05-28	诺华股份有限公司	用于癌症治疗的组合及其应用
CN104546745A (zh) *	2013-10-14	2015-04-29	深圳海王药业有限公司	醋酸阿比特龙的片剂组合物及其制备工艺
US10722527B2 (en)	2015-04-10	2020-07-28	Capsugel Belgium Nv	Abiraterone acetate lipid formulations
UA124972C2 (uk)	2016-07-29	2021-12-22	Янссен Фармацевтика Нв	Способи лікування раку передміхурової залози
HUE060460T2 (hu) *	2017-04-13	2023-03-28	Janssen Pharmaceutica Nv	Niraparib, abirateron-acetát és prednizon prosztatarák kezelésére
US10702508B2 (en)	2017-10-16	2020-07-07	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN109718198A (zh) *	2017-10-30	2019-05-07	浙江京新药业股份有限公司	一种治疗前列腺癌的注射剂及其制备方法
US10792292B2 (en) *	2019-03-06	2020-10-06	Propella Therapeutics, Inc.	Abiraterone prodrugs
WO2021031991A1 (zh) *	2019-08-16	2021-02-25	中国科学院分子细胞科学卓越创新中心	治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
CN115427016A (zh) *	2020-04-16	2022-12-02	塔凡塔医疗匈牙利公司	用于治疗前列腺癌的方法和组合物
CN114560903B (zh) *	2022-03-09	2023-08-01	绍兴市上虞区武汉理工大学高等研究院	一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en)	2024-03-01	2025-09-01	Alfasan Nederland B V	17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5604213A (en)	1992-03-31	1997-02-18	British Technology Group Limited	17-substituted steroids useful in cancer treatment
CA2132449C (en)	1992-03-31	2002-09-10	Susan E. Barrie	17 - substituted steroids useful in cancer treatment
EP1276482B1 (en) *	2000-03-02	2008-01-16	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Combination chemotherapy
WO2002053138A2 (en) *	2001-01-02	2002-07-11	Elisabeth Shanahan-Prendergast	Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
SI1556058T1 (sl) *	2002-10-23	2008-02-29	Pantarhei Bioscience Bv	Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
WO2004062620A2 (en) *	2003-01-13	2004-07-29	Cedars-Sinai Medical Center	Paricalcitol as a chemotherapeutic agent
US20060030608A1 (en) *	2004-08-04	2006-02-09	Boehringer Ingelheim Pharmaceuticals, Inc.	Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) *	2004-08-24	2004-09-29	Btg Int Ltd	Novel salt forms
PL2478907T3 (pl)	2006-08-25	2021-10-25	Janssen Oncology, Inc.	Kompozycje do leczenia nowotworu

2007
- 2007-08-23 PL PL12160586T patent/PL2478907T3/pl unknown
- 2007-08-23 PT PT78373263T patent/PT2061561E/pt unknown
- 2007-08-23 KR KR1020097005974A patent/KR20090059126A/ko not_active Ceased
- 2007-08-23 NZ NZ597830A patent/NZ597830A/xx not_active IP Right Cessation
- 2007-08-23 CN CN201410261671.3A patent/CN104306977A/zh active Pending
- 2007-08-23 ES ES12160586T patent/ES2869343T3/es active Active
- 2007-08-23 CA CA2661422A patent/CA2661422C/en active Active
- 2007-08-23 ES ES07837326T patent/ES2428634T3/es active Active
- 2007-08-23 PL PL07837326T patent/PL2061561T3/pl unknown
- 2007-08-23 EP EP20190748.2A patent/EP3804730A1/en not_active Withdrawn
- 2007-08-23 WO PCT/US2007/018769 patent/WO2008024484A1/en not_active Ceased
- 2007-08-23 KR KR1020157025243A patent/KR20150108946A/ko not_active Ceased
- 2007-08-23 LT LTEP12160586.9T patent/LT2478907T/lt unknown
- 2007-08-23 AU AU2007287098A patent/AU2007287098C1/en active Active
- 2007-08-23 DK DK07837326.3T patent/DK2061561T3/da active
- 2007-08-23 KR KR1020177037293A patent/KR20180003636A/ko not_active Ceased
- 2007-08-23 KR KR1020207031218A patent/KR20200125776A/ko not_active Ceased
- 2007-08-23 HR HRP20130961TT patent/HRP20130961T1/hr unknown
- 2007-08-23 JP JP2009525647A patent/JP2010501575A/ja active Pending
- 2007-08-23 SI SI200731334T patent/SI2061561T1/sl unknown
- 2007-08-23 HU HUE12160586A patent/HUE054495T2/hu unknown
- 2007-08-23 EP EP07837326.3A patent/EP2061561B1/en not_active Revoked
- 2007-08-23 DK DK12160586.9T patent/DK2478907T3/da active
- 2007-08-23 RS RS20130401A patent/RS52956B/sr unknown
- 2007-08-23 EP EP12160586.9A patent/EP2478907B1/en not_active Revoked
- 2007-08-23 PT PT121605869T patent/PT2478907T/pt unknown
- 2007-08-23 RS RS20210531A patent/RS62034B1/sr unknown
- 2007-08-23 SI SI200732177T patent/SI2478907T1/sl unknown
- 2007-08-23 CN CNA2007800385835A patent/CN101528308A/zh active Pending
2009
- 2009-02-24 IL IL197211A patent/IL197211A0/en unknown
- 2009-03-20 NO NO20091190A patent/NO20091190L/no not_active Application Discontinuation
2011
- 2011-12-15 JP JP2011273983A patent/JP6053279B2/ja active Active
2013
- 2013-08-01 IL IL227746A patent/IL227746A0/en unknown
- 2013-08-20 CY CY20131100709T patent/CY1115477T1/el unknown
2014
- 2014-12-17 JP JP2014254864A patent/JP2015110577A/ja active Pending
2015
- 2015-08-31 AU AU2015221447A patent/AU2015221447B9/en not_active Ceased
2016
- 2016-11-17 JP JP2016224393A patent/JP2017052791A/ja active Pending
2017
- 2017-03-15 AU AU2017201764A patent/AU2017201764A1/en not_active Abandoned
- 2017-12-20 JP JP2017243588A patent/JP6445123B2/ja active Active
2018
- 2018-02-22 IL IL257681A patent/IL257681A/en unknown
- 2018-11-28 JP JP2018222531A patent/JP2019059750A/ja not_active Withdrawn
- 2018-11-29 AU AU2018271331A patent/AU2018271331A1/en not_active Abandoned
2020
- 2020-03-27 JP JP2020057344A patent/JP6740497B2/ja active Active
- 2020-07-01 NO NO20200775A patent/NO20200775A1/no not_active Application Discontinuation
- 2020-11-20 JP JP2020193403A patent/JP2021038252A/ja not_active Withdrawn
2021
- 2021-03-16 AU AU2021201649A patent/AU2021201649A1/en not_active Ceased
- 2021-04-27 HR HRP20210670TT patent/HRP20210670T1/hr unknown
- 2021-06-10 CY CY20211100513T patent/CY1124221T1/el unknown
2022
- 2022-07-18 AU AU2022206696A patent/AU2022206696A1/en not_active Abandoned
- 2022-10-06 JP JP2022161610A patent/JP2022185091A/ja not_active Withdrawn
2024
- 2024-08-22 JP JP2024140948A patent/JP2024164147A/ja active Pending

Also Published As

Publication number	Publication date
AU2007287098A1 (en)	2008-02-28
ES2428634T3 (es)	2013-11-08
DK2478907T3 (da)	2021-05-25
JP6445123B2 (ja)	2018-12-26
DK2061561T3 (da)	2013-10-07
CA2661422C (en)	2017-06-27
AU2017201764A1 (en)	2017-04-06
JP2012082215A (ja)	2012-04-26
EP3804730A1 (en)	2021-04-14
EP2478907A2 (en)	2012-07-25
KR20150108946A (ko)	2015-09-30
JP2020114851A (ja)	2020-07-30
HRP20130961T1 (hr)	2013-11-22
JP6053279B2 (ja)	2016-12-27
JP2024164147A (ja)	2024-11-26
SI2478907T1 (sl)	2021-08-31
CN104306977A (zh)	2015-01-28
AU2015221447A1 (en)	2015-09-17
AU2015221447B2 (en)	2016-12-15
IL227746A0 (en)	2013-09-30
AU2021201649A1 (en)	2021-04-08
EP2061561B1 (en)	2013-07-10
AU2018271331A1 (en)	2018-12-20
AU2007287098C1 (en)	2018-03-15
CN101528308A (zh)	2009-09-09
CY1124221T1 (el)	2022-05-27
KR20180003636A (ko)	2018-01-09
JP2015110577A (ja)	2015-06-18
EP2478907B1 (en)	2021-04-14
HK1131577A1 (en)	2010-01-29
IL197211A0 (en)	2009-12-24
JP2017052791A (ja)	2017-03-16
EP2061561A1 (en)	2009-05-27
RS52956B (sr)	2014-02-28
HRP20210670T1 (hr)	2021-06-11
JP2010501575A (ja)	2010-01-21
IL257681A (en)	2018-04-30
ES2869343T3 (es)	2021-10-25
JP2019059750A (ja)	2019-04-18
NO20091190L (no)	2009-03-20
JP2018065859A (ja)	2018-04-26
AU2022206696A1 (en)	2022-08-11
JP2022185091A (ja)	2022-12-13
PT2478907T (pt)	2021-05-26
RS62034B1 (sr)	2021-07-30
AU2007287098B2 (en)	2013-08-15
NZ597830A (en)	2013-02-22
CA2661422A1 (en)	2008-02-28
NO20200775A1 (no)	2009-03-20
PL2478907T3 (pl)	2021-10-25
WO2008024484A1 (en)	2008-02-28
KR20200125776A (ko)	2020-11-04
KR20090059126A (ko)	2009-06-10
HUE054495T2 (hu)	2021-09-28
JP2021038252A (ja)	2021-03-11
EP2478907A3 (en)	2012-08-01
SI2061561T1 (sl)	2013-11-29
LT2478907T (lt)	2021-06-25
JP6740497B2 (ja)	2020-08-12
PL2061561T3 (pl)	2013-12-31
AU2015221447B9 (en)	2017-07-20
CY1115477T1 (el)	2017-01-04

Publication	Publication Date	Title
PT2061561E (pt)	2013-10-09	Composições para tratar o cancro
EP2425874A3 (en)	2013-05-15	Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer
WO2008021368A3 (en)	2008-07-10	Compositions and methods for neuroprotection
WO2007144152A3 (en)	2008-06-12	Extended step-down estrogen regimen
WO2010081032A3 (en)	2010-11-04	Steroidal compositions
WO2010088409A3 (en)	2011-02-17	Methods of neuroprotection using neuroprotective steroids and a vitamin d
UA94909C2 (ru)	2011-06-25	Фармацевтическая композиция нейроактивного стероида и ее применение
UA95310C2 (ru)	2011-07-25	Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
WO2010091299A3 (en)	2010-10-21	Combination of a 17 alpha-hydr0xylase/c17, 20-lyase inhibitor with an additional therapeutic agent
MX2008011633A (es)	2008-12-16	Aminoquinolonas como inhibidores de gsk-3.
TW200603831A (en)	2006-02-01	Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds
WO2011049948A3 (en)	2011-06-16	Neuroprotection and myelin repair using nestorone®
WO2008011073A3 (en)	2008-10-23	Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
WO2009139924A3 (en)	2010-04-01	Controlled release corticosteroid compositions and methods for the treatment of otic disorders
WO2004075832A3 (en)	2005-03-24	Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
EP2023926A4 (en)	2010-08-04	PYRIDONECARBOXAMIDE DERIVATIVES USEFUL FOR TREATING HYPERPROLIFERATIVE AND ANGIOGENESIS RELATED DISORDERS
WO2006089150A3 (en)	2006-11-02	Antiangiogenic agents with aldesleukin
MXPA02007117A (es)	2004-08-23	Composiciones para suministrar un antagonista de cortisol..
WO2011022838A8 (en)	2011-06-16	Polyhydroxylated bile acids for treatment of biliary disorders
WO2008079270A3 (en)	2008-10-16	Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
NZ586759A (en)	2012-08-31	Aqueous-alcoholic, single-phase transcutaneous pharmaceutical compositions containing a steroid hormone
WO2009035634A3 (en)	2009-06-04	Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2007123848A3 (en)	2008-11-27	Therapeutic compositions containing modified class i slrp proteins
SE0400346D0 (sv)	2004-02-13	Steroids for cancer treatment
AU2003233733A1 (en)	2003-12-22	Compositions for cancer therapy saponins or sapogenins